<?xml version="1.0" encoding="UTF-8"?>
<p id="Par40">Additionally, the small sample sizes of literature included in our review indicate a fractured research response. It has been estimated that a sample size of 800 patients is required to power a randomised controlled trial of an NAI in hospitalised patients [
 <xref ref-type="bibr" rid="CR24">24</xref>]. No prospective research identified here was that large. Beyond the benefits of increased enrolment and external validity, multicentre research has specific advantages in epidemics. It can compensate for unexpected variations in epidemiology at the regional level (such as the sudden end to the EVD outbreak in Liberia that prematurely halted a clinical treatment trial) [
 <xref ref-type="bibr" rid="CR25">25</xref>] or the temporary closure of health care facilities with nosocomial transmission (such as occurred during the SARS outbreak of 2003) [
 <xref ref-type="bibr" rid="CR26">26</xref>].
</p>
